Articles published in Journal of Diabetes & Metabolism have been cited by esteemed scholars and scientists all around the world. Journal of Diabetes & Metabolism has got h-index 44, which means every article in Journal of Diabetes & Metabolism has got 44 average citations.
Following are the list of articles that have cited the articles published in Journal of Diabetes & Metabolism.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
Total published articles |
123 | 107 | 59 | 61 | 45 | 23 |
Research, Review articles and Editorials |
44 | 54 | 37 | 40 | 21 | 22 |
Research communications, Review communications, Editorial communications, Case reports and Commentary |
5 | 1 | 2 | 5 | 3 | 0 |
Conference proceedings |
6 | 16 | 5 | 7 | 0 | 45 |
Citations received as per Google Scholar, other indexing platforms and portals |
632 | 946 | 1156 | 1199 | 1039 | 1106 |
| Journal total citations count | 11096 |
| Journal impact factor | 12.50 |
| Journal 5 years impact factor | 18.23 |
| Journal cite score | 23.62 |
| Journal h-index | 44 |
| Journal Impact Factor 2020 formula |
| IF= Citations(y)/{Publications(y-1)+ Publications(y-2)} Y= Year |
| Journal 5-year Impact Factor 2020 formula |
| Citations(2016 + 2017 + 2018 + 2019 + 2020)/ {Published articles(2016 + 2017 + 2018 + 2019 + 2020)} |
| Journal citescore |
| Citescorey = Citationsy + Citationsy-1 + Citationsy-2 + Citations y-3 / Published articlesy + Published articlesy-1 + Published articlesy-2 + Published articles y-3 |
Venditti EM, Kramer MK. Diabetes Prevention Program community outreach: perspectives on lifestyle training and translation. American journal of preventive medicine. 2013 Apr 30;44(4):S339-45. |
|
Williams LB, Sattin RW, Dias J, Garvin JT, Marion L, Joshua T, Kriska A, Kramer MK, Echouffo-Tcheugui JB, Freeman A, Narayan KV. Design of a cluster-randomized controlled trial of a diabetes prevention program within African–American churches: the fit body and soul study. Contemporary clinical trials. 2013 Mar 31;34(2):336-47. |
|
Dunkley AJ, Bodicoat DH, Greaves CJ, Russell C, Yates T, Davies MJ, Khunti K. Diabetes Prevention in the real world: Effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations. Diabetes care. 2014 Apr 1;37(4):922-33. |
|
Schwartz SS, Zangeneh F (2016) Evidence-based practice use of quick-release bromocriptine across the natural history of type 2 diabetes mellitus. Postgraduate Medicine 128: 828-838. |
|
Chamarthi B, Ezrokhi M, Rutty D, Cincotta AH (2016) Impact of bromocriptine-QR therapy on cardiovascular outcomes in type 2 diabetes mellitus subjects on metformin. Postgraduate Medicine 128: 761-769. |
|
Grunberger G (2014) Bromocriptine mesylate QR in treatment of Type 2 diabetes. Diabetes Management 19: 203-211. |
|
Assad C, Mosah HA, Hashim HM, Khazaal FA. Effect of Cabergoline added to Metformin on Glycemic Control, Insulin Resistance and Beta Cell Function in Obese type 2 Diabetic Patients. Global Journal of Medical Research. 2014 Oct 25;14(5). |
|
Raskin P, Cincotta AH. Bromocriptine-QR therapy for the management of type 2 diabetes mellitus: developmental basis and therapeutic profile summary. Expert Review of Endocrinology & Metabolism. 2016 Mar 3;11(2):113-48. |
|
Chamarthi B, Gaziano JM, Blonde L, Vinik A, Scranton RE, Ezrokhi M, Rutty D, Cincotta AH. Timed Bromocriptine-QR therapy reduces progression of cardiovascular disease and dysglycemia in subjects with well-controlled type 2 diabetes mellitus. Journal of diabetes research. 2015 Apr 28;2015. |
|
Liang W, Gao L, Li N, Wang B, Wang L, et al. (2015) Efficacy and safety of bromocriptine-QR in type 2 diabetes: a systematic review and meta-analysis. Hormone and Metabolic Research 47: 805-812. |
|
Vinik A, Cincotta A, Scranton R, Bohannon N, Ezrokhi M, Gaziano J (2012) Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents. Endocrine Practice 18: 931-943. |
|
Garber A, Blonde L, Bloomgarden Z, Handelsman Y, Dagogo-Jack S. The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations. Endocrine Practice. 2013 Jan 21. |
|
Kang I, Buckner T, Shay NF, Gu L, Chung S. Improvements in metabolic health with consumption of ellagic acid and subsequent conversion into urolithins: evidence and mechanisms. Advances in nutrition. 2016 Sep 7;7(5):961-72. |
|
Soumya D, Srilatha B. Late stage complications of diabetes and insulin resistance. J Diabetes Metab. 2011 Dec 25;2(9):1000167. |
|
Martin H, Burgess EJ, Smith WA, McGhie TK, Cooney JM, Lunken RC, de Guzman E, Trower T, Perry NB. JAK2 and AMP-kinase inhibition in vitro by food extracts, fractions and purified phytochemicals. Food & function. 2015;6(1):304-11. |
|
Kaur R, Parveen S, Mehan S, Khanna D, Kalra S. Neuroprotective effect of ellagic acid against chronically scopolamine induced Alzheimer’s type memory and cognitive dysfunctions: possible behavioural and biochemical evidences. Int. J. Preven. Med. Res. 2015;1:45-64. |
|
Kaur R, Mehan S, Khanna D, Kalra S. Ameliorative treatment with ellagic acid in scopolamine induced Alzheimer's type memory and cognitive dysfunctions in rats. Aust J Clin Neurol. 2015;2:1-1. |
|
Arun Kumar R, Sathish Kumar D, Nishanth T. A review on stem cell research & their role in various diseases. J Stem Cell Res Ther. 2011;1(112):2. |
|
Rodríguez-González S, Gutiérrez-Ruíz IM, Pérez-Ramírez IF, Mora O, Ramos-Gomez M, Reynoso-Camacho R. Mechanisms related to the anti-diabetic properties of mango (Mangifera indica L.) juice by-product. Journal of functional foods. 2017 Oct 1;37:190-9. |
|
Soumya D, Srilatha B. Late stage complications of diabetes and insulin resistance. J Diabetes Metab. 2011 Dec 25;2(9):1000167. |
|
